Low body mass index correlated with higher incidence of cardiovascular disease; the lowest risk was seen at a body mass index of 22 to 23 kg/m2.
Your search for comorbidities returned 146 results
Click on a filter below to refine your search. Remove a filter to broaden your search.
After adjustments, results remained significant for both CV death and all-cause mortality,
Treatment with canagliflozin may not significantly lower risk for myocardial infarction among patients with type 2 diabetes and comorbid chronic kidney disease or among patients with diabetes who have a history of or have a high risk for CVD.
Cardiovascular events are the leading cause of death among patients with chronic kidney disease, and metabolic acidosis in this population is underdiagnosed.
Several associations, including the AHA, ACC, and NLA, have issued new guidelines for management of patients with chronic coronary disease.
A study was conducted to determine the long-term clinical impact of initial statin dose following myocardial infarction.
Investigators assessed the impact of treatment with empagliflozin on patients with type 2 diabetes and chronic obstructive pulmonary disease.
The risk for recurrent MACE was high among survivors of a first ever acute coronary syndrome with a substantial number of these being fatal; 34.4% had MACE within 1 year and 48.4% in 3 years.
The decision to undergo partial instead of radical nephrectomy should be individualized, according to investigators.